Atomo’s innovative Rapid Diagnostic Test (RDT) platforms simplify procedures, mitigate common user errors and enhance test performance. Atomo products are currently approved for distribution in over 40 countries.

COVID-19 Test
Atomo’s platform is a natural fit for a fast, accurate point of care diagnostic for COVID-19. Atomo offers an antigen test for the qualitative detection of nucleocapsid protein antigens specific to the SARS-CoV-2 virus, as well as an antibody test to indicate if a user has protection from the virus.

HIV 1&2 Test
Atomo offers the world’s first integrated, blood-based rapid diagnostic test (RDT) for HIV screening. Recognized globally for innovative design, performance and ease-of-use. With 99.6% specificity, 99.6% sensitivity, low blood volume and a 24 month shelf life, this test could save 40,000 lives per year in Africa alone.
